New Approaches in the Management of Inhibitor Patients
- 1 March 2006
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 115 (3-4), 172-179
- https://doi.org/10.1159/000090931
Abstract
The most serious current complication of factor replacement therapy for hemophilia patients is the development of neutralizing antibodies to the factor termed inhibitors. Patients with high-titer inhibitors frequently develop serious bleeding complications which do not respond to standard factor replacement therapy. Therefore, they must be treated with the so-called bypassing agents, recombinant factor VIIa and activated prothrombin complex concentrates, neither of which is as effective as standard factor replacement in patients without inhibitors. Immune tolerance therapy aimed at eradicating inhibitors is successful in a majority of patients; however, a sizable minority will have life-long inhibitors and often develop debilitating joint disease. The ultimate goal is to develop strategies aimed at preventing inhibitor development though these have not been realized yet. Until this is achieved, additional novel approaches are needed to improve the treatment of bleeding episodes and to better treat arthropathy once it develops. Finally, there is no laboratory monitoring device which can predict the clinical response of patients to bypassing agents. Thus another goal of current research is to develop such a tool which will enable the individualization of bypassing agent.Keywords
This publication has 30 references indexed in Scilit:
- Prophylactic recombinant factor VIIa in haemophilia patients with inhibitorsHaemophilia, 2005
- Rofecoxib as adjunctive therapy for haemophilic arthropathyHaemophilia, 2005
- Dose and response in haemophilia – optimization of factor replacement therapyBritish Journal of Haematology, 2004
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia AJournal of Thrombosis and Haemostasis, 2004
- Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIIIJournal of Thrombosis and Haemostasis, 2004
- Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophiliaBritish Journal of Haematology, 2004
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxibThe American Journal of Cardiology, 2003
- Phosphate-32 Colloid Radiosynovectomy in HemophiliaClinical Orthopaedics and Related Research, 2001